Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | PDE5A | O76074 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784099 | 1.00 | PDGFRB (0.56) | PDGFRBPDGFRAKDM4ELMNANPC1 | |
| SCHEMBL4498560 | 1.00 | PDGFRB (0.56) | PDGFRBPDGFRAKDM4ELMNANPC1 | |
| SCHEMBL3539961 | 0.90 | PDGFRB (0.46) | PDGFRBPDGFRAKDM4ELMNANPC1 | |
| SCHEMBL3539965 | 0.90 | PDGFRB (0.46) | PDGFRBPDGFRAKDM4ELMNANPC1 | |
| SCHEMBL6600134 | 0.83 | PDGFRB (0.44) | PDGFRBPDGFRAKDM4ELMNANPC1 | |
| SCHEMBL1784501 | 0.78 | KDM4E (0.45) | PDGFRBPDGFRAKDM4ENPC1ALDH1A1 | |
| SCHEMBL21001885 | 0.77 | KDM4E (0.57) | KDM4ELMNANPC1RAB9AHTT | |
| SCHEMBL21001886 | 0.77 | KDM4E (0.57) | KDM4ELMNANPC1RAB9AHTT | |
| SCHEMBL15386056 | 0.77 | TRPV1 (0.46) | PDGFRBPDGFRAKDM4ENPC1RAB9A | |
| SCHEMBL12402770 | 0.76 | MAPT (0.44) | PDGFRBPDGFRAKDM4ERAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4240339-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | Fred Hutchinson Cancer Center (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER CENTER (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2022098776-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20210113573-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC REGENERATION | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2021-04-22 | — | — | US | disclosed |
| CN-110170054-B | Small molecule drug targeting MDM2 zinc finger domain and anti-tumor application thereof | 徐州医科大学 | 2020-03-31 | — | — | CN | disclosed |
| CN-110170054-A | Target the small-molecule drug and its anticancer usage of MDM2 Zinc finger domain | 徐州医科大学 | 2019-08-27 | — | — | CN | disclosed |
| US-9951029-B2 | Styryl quinazoline derivatives as pharmaceutically active agents | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2018-04-24 | — | — | US | disclosed |
| US-9951029-B2 | Styryl quinazoline derivatives as pharmaceutically active agents | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2018-04-24 | — | — | US | disclosed |
| US-9951029-B2 | Styryl quinazoline derivatives as pharmaceutically active agents | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2018-04-24 | — | — | US | disclosed |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
| CN-101460490-A | Substituted ring fused azines and their use in cancer therapy | AUCKLAND UNISERVICES LTD (NZ) | 2009-06-17 | — | — | CN | disclosed |
| EP-1854509-A2 | Methods and compositions for restoring conformational stability of a protein of the p53 family | Pfizer Products Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1484060-A2 | Methods and compositions for restoring conformational stability of a protein of the p53 family | Pfizer Products Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| EP-1480042-A2 | Method of screening compounds interacting with proteins of the p53 family | Pfizer Products Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20020048271-A1 | Methods and composition for restoring conformational stability of a protein of the p53 family | RASTINEJAD FARZAN (US) | 2002-04-25 | — | — | US | disclosed |
| CN-1329493-A | Methods and compositions for restoring conformational stability of proteins of the p53 family | PFIZER PROD INC (US) | 2002-01-02 | — | — | CN | disclosed |
| EP-1137418-A2 | METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000032175-A2 | METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY | PFIZER PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| CN-1035825-A | Quinazoline derivant | LILLY CO ELI (US) | 1989-09-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210113573-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC REGENERATION | BMP4, NOD2, BMP2 | PDGFRB 2119/4885PDGFRA 3178/4885KDM4E 3413/4885 |
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | CDC42, BMP4, TPMT | PDGFRB 4071/4885PDGFRA 4433/4885KDM4E 2577/4885 |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | BMP4, P2RY2, GPR39 | PDGFRB 503/4885PDGFRA 817/4885KDM4E 4697/4885 |
| US-20020048271-A1 | Methods and composition for restoring conformational stability of a protein of the p53 family | TP53, TP53BP1, BCCIP | PDGFRB 4666/4885PDGFRA 4582/4885KDM4E 1463/4885 |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | PDGFRB 122/4885PDGFRA 73/4885KDM4E 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.